Company Overview and News

 
KUB buys leasehold land in Klang for RM25mil

2018-09-26 thestar.com.my
Notably, last week, KUB completed the disposal of its fast-food restaurant A&W Malaysia for RM34mil, after two years of discussions. For the proposed acquisition, KUB said it would be satisfied by cash from internally generated funds.
6874 BSMAF 1818

 
KLCI seen extending consolidation, firm crude oil price to offer respite

2018-09-26 theedgemarkets
KUALA LUMPUR (Sept 26): The FBM KLCI is expected to continue its consolidation phase and hover below the 1,800-point level but may find some respite from high crude oil prices.
1201 5016 6556 7668 5219 4405 6874 2143 5189

 
KLCI seen extending consolidation, firm crude oil to offer respite

2018-09-25 theedgemarkets
KUALA LUMPUR (Sept 26): The FBM KLCI is expected to continue its consolidation phase and hover below the 1,800-point level but may find some respite from high crude oil prices.
1201 5016 6556 7668 5219 4405 6874 2143 5189

 
Sapura Energy, ECM Libra, Hai-O, Velesto, Maxwell, Deleum, Pestech, OpenSys, Sumatec, KUB, V.S. Industry, Ann Joo, Maybulk, Tan Chong Motor and Warisan TC Holdings

2018-09-25 theedgemarkets
KUALA LUMPUR (Sept 25): Based on corporate announcements and news flow today, companies in focus on Wednesday (Sept 26) may include: Sapura Energy Bhd, ECM Libra Financial Group Bhd, Hai-O Enterprise Bhd, Velesto Energy Bhd, Maxwell International Holdings Bhd, Deleum Bhd, Pestech International Bhd, OpenSys (M) Bhd, Sumatec Resources Bhd, KUB Malaysia Bhd, V.S. Industry Bhd, Ann Joo Resources Bhd, Malayan Bulk Carriers Bhd (Maybulk), Tan Chong Motor Holdings Bhd and Warisan TC Holdings Bhd
PBLOF 6874 1295 2143 5189 1201 5016 6556 7668 5219 4405 BSMAF 1818

 
KUB buys land in Klang for RM25m

2018-09-25 theedgemarkets
KUALA LUMPUR (Sept 25): KUB Malaysia Bhd is acquiring a piece of leasehold land in Klang for RM25 million for its business expansion.
6874 BSMAF 1818

 
Stock With Momentum: KUB Malaysia

2018-08-20 theedgemarkets
KUB Malaysia Bhd (-ve) KUB Malaysia Bhd (fundamental: 1.8/3; valuation: 3/3), which saw 5.41 million shares traded last Friday compared to its 200-day average of 1.89 million shares, settled one sen or 2.8% higher at 36.5 sen, giving it a market capitalisation of RM203.11 million.
6874

 
KUB plans to dispose of A&W PJ land

2018-08-03 malaymail
KLANG, Aug 3 — KUB Malaysia Bhd’s plan to dispose of its fast food chain business, A&W Malaysia Sdn Bhd will be completed by month-end, and the diversified group is also likely to sell the 0.42 hectare plot of land of its iconic A&W outlet in Petaling Jaya.
6874

 
KUB 'more likely' to dispose of PJ A&W land

2018-08-03 theedgemarkets
KLANG (Aug 3): KUB Malaysia Bhd is 'more likely' to dispose of its 1.05-acre land in Petaling Jaya, where the landmark A&W PJ Drive-In is situated, according to its president and group managing director Datuk Abdul Rahim Mohd Zin
6874

 
MISC, Red Sena, Top Glove, KUB Malaysia, Ta Ann, Protasco and Versatile Creative

2018-07-06 theedgemarkets
KUALA LUMPUR (July 6): Based on corporate announcements and news flow today, stocks that may draw some attention on Monday (July 9) could be MISC, Red Sena, Top Glove, KUB Malaysia, Ta Ann, Protasco and Versatile Creative.
TGLVY 4995 5270 7113 TPGVF 6874 BSMAF 5012 1818

 
KUB to dispose entire interest in A&W for RM34m

2018-07-06 theedgemarkets
KUALA LUMPUR (July 6): Restoran Kualiti Sdn Bhd (RKSB), a wholly-owned subsidiary of KUB Malaysia Bhd, entered into a sale and purchase agreement (SPA) today with Inter Mark Resources Sdn Bhd (IMRSB) for the disposal of its entire 100% interest in A&W (Malaysia) Sdn Bhd for RM34 million.
6874 BSMAF 1818

 
KUB consolidating, says AllianceDBS Research

2018-07-02 theedgemarkets
KUALA LUMPUR (July 2): AllianceDBS Research said KUB Malaysia Bhd (KUB) had on June 29 traded within previous day’s range to form an inside day bar before closing at 32 sen (up 1 sen or 3.22%).
6874

 
KUB still looking to sell A&W

2018-06-29 thestar.com.my
“We have to choose to either expand our core business, particularly the LPG business, which contributes to 70% of KUB’s revenue and 60% of our earnings or focus on the food business which only contributes about 10% of KUB’s revenue,” Abdul Rahim explained., - The Star pic by KAMARUL ARIFFIN shows Abdul Rahim speaking aft the media conference yesterday.
6874

9
KLCI seen trading in a tight range on window dressing activities

2018-06-28 theedgemarkets
KUALA LUMPUR (June 29): The FBM KLCI is expected to trade in a tight range today after on some mild window dressing activities on the final trading day of the first half of 2018 after having dropped some 131 points year-to-date.
5139 5347 8206 0900 TNABY 6874 TNABF 8583 5222 5255 2593

9
EcoWorld, EWI, KUB, Aeon Credit, FGV, Icon Offshore, TNB, Mah Sing, United Malacca and Berjaya Corp

2018-06-28 theedgemarkets
KUALA LUMPUR (June 28): Based on corporate announcements and news flow today, stocks in focus on Friday (June 29) may include the following: Eco World Development Group Bhd, Eco World International Bhd, KUB Malaysia Bhd, Aeon Credit Service (M) Bhd, Felda Global Ventures Holdings Bhd, Icon Offshore Bhd, Tenaga Nasional Bhd, Mah Sing Group Bhd, United Malacca Bhd and Berjaya Corp Bhd.
5139 5347 8206 0900 TNABY 6874 TNABF 8583 5255 5222 2593

 
KUB to finally commence work on flagship building in PJ next year

2018-06-28 theedgemarkets
SHAH ALAM (June 28): Having obtained a development order, KUB Malaysia Bhd expects to finally kick-start development of its flagship commercial building in Petaling Jaya next year on a plot of land where the landmark A&W Restaurant is sited.
6874

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...